CD274 and neoplasm: Novel biomarkers that further characterise the composition of the tumour microenvironment, as well as the tumour immune profile and microbiome, hold promise for extending current predictive biomarkers beyond programmed death ligand 1 (PD-L1) expression and tumour mutational burden (TMB).